---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-198411"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:05:27.301250+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# IN8bio reports 100% AML remission with INB-100; FDA guidance for registrational trial

## Summary
- 100% of AML patients in Phase 1 trial remain in complete remission; all relapse-free beyond one year.
- Received FDA guidance for registrational trial of INB-100 in AML; IND submission planned Q1 2025.
- INB-200 for GBM shows prolonged survival in higher dose cohorts; one MGMT-unmethylated patient in remission >1 year.
- No new relapses since May 15, 2024; safety manageable with no significant cell therapy-related toxicities.
- INB-400 Phase 2 trial for front-line GBM actively enrolling at multiple US sites.

## SEC filing metadata
- accession: 0001193125-24-198411
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000119312524198411/0001193125-24-198411-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000119312524198411/d801512d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-198411
- JSON: https://secwatch.observer/filing/0001193125-24-198411.json
- Plain text: https://secwatch.observer/filing/0001193125-24-198411.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.